PMID- 21823552
OWN - NLM
STAT- MEDLINE
DCOM- 20110823
LR  - 20191112
IS  - 1551-7489 (Print)
IS  - 1551-7489 (Linking)
VI  - 7
IP  - 3
DP  - 2011 May-Jun
TI  - Analgesic and adverse effects of a fixed-ratio morphine-oxycodone combination 
      (MoxDuo) in the treatment of postoperative pain.
PG  - 217-28
AB  - OBJECTIVE: To compare efficacy and safety profiles of an immediate-release 
      morphine and oxycodone Dual-Opioid combination (MoxDuo) versus its individual 
      components and versus its morphine-equivalent doses in moderate to severe 
      postoperative pain patients. DESIGN: Randomized, double-blind, 48-hour, 
      parallel-treatment, multicenter, six-arm study of MoxDuo. SETTING: Six US 
      centers. PATIENTS: Within 6 hours after bunionectomy surgery, patients were 
      eligible if they reported pain intensity > or = 2 on the 4-point Likert scale and 
      > or = 4 on an 11-point Numerical Pain Rating Scale (197 randomly assigned; 175 
      completers). INTERVENTIONS: MoxDuo 12 mg/8 mg, MoxDuo 6 mg/4 mg, morphine 12 mg, 
      oxycodone 8 mg, morphine 6 mg, or oxycodone 4 mg (all administered q6h). MAIN 
      OUTCOME MEASURE: Sum of pain intensity differences 0-24 hours after the first 
      dose of study medication (SPID24) and percentage of patients with moderate to 
      severe nausea, emesis, or dizziness. RESULTS: SPID24 was significantly better in 
      the MoxDuo 12 mg/8 mg group when compared with its individual components 
      (morphine 12 mg [p = 0.009] and oxycodone 8 mg [p = 0.037]), and when compared 
      with MoxDuo 6 mg/4 mg (p = 0.011; 54.3 vs 28.5, 35.7, and 30.0, respectively). 
      MoxDuo6 mg/4 mg and its morphine-equivalent doses (morphine 12 mg and oxycodone 8 
      mg) had comparable analgesic effects. There was a 50-75 percent reduction in 
      moderate to severe adverse events (AEs) commonly associated with opioids (ie, 
      nausea, vomiting, and dizziness) in the MoxDuo 6 mg/4 mg group when compared with 
      its morphine-equivalent dose groups. CONCLUSIONS: MoxDuo produced superior 
      analgesic effects when compared with its individual components, but comparable 
      efficacy when compared with its morphine-equivalent doses. Common AEs were 
      reduced at least 50 percent with MoxDuo when compared with its 
      morphine-equivalent doses. MoxDuo may be an improved intervention in the 
      management of moderate to severe acute pain.
FAU - Richards, Patricia
AU  - Richards P
AD  - QRxPharma, Inc., Clinical Research, Bedminster, New Jersey, USA.
FAU - Riff, Dennis
AU  - Riff D
FAU - Kelen, Robin
AU  - Kelen R
FAU - Stern, Warren
AU  - Stern W
CN  - MoxDuo Study Team
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Opioid Manag
JT  - Journal of opioid management
JID - 101234523
RN  - 0 (Analgesics, Opioid)
RN  - 0 (Drug Combinations)
RN  - 76I7G6D29C (Morphine)
RN  - CD35PMG570 (Oxycodone)
SB  - IM
MH  - Adult
MH  - Analgesics, Opioid/administration & dosage/adverse effects/*therapeutic use
MH  - Dizziness/chemically induced
MH  - Double-Blind Method
MH  - Drug Combinations
MH  - Female
MH  - Hallux Valgus/surgery
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Morphine/administration & dosage/adverse effects/*therapeutic use
MH  - Oxycodone/administration & dosage/adverse effects/*therapeutic use
MH  - Pain Measurement/drug effects
MH  - Pain, Postoperative/*drug therapy
MH  - Postoperative Nausea and Vomiting/epidemiology
FIR - Diamond, E
IR  - Diamond E
FIR - Gottlieb, I
IR  - Gottlieb I
FIR - Raymond, G
IR  - Raymond G
FIR - Riff, D
IR  - Riff D
FIR - Seegmiller, D
IR  - Seegmiller D
FIR - Tallis, A
IR  - Tallis A
EDAT- 2011/08/10 06:00
MHDA- 2011/08/24 06:00
CRDT- 2011/08/10 06:00
PHST- 2011/08/10 06:00 [entrez]
PHST- 2011/08/10 06:00 [pubmed]
PHST- 2011/08/24 06:00 [medline]
AID - 10.5055/jom.2011.0064 [doi]
PST - ppublish
SO  - J Opioid Manag. 2011 May-Jun;7(3):217-28. doi: 10.5055/jom.2011.0064.